Modalis Therapeutics Corporation
4883.T
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.89B
Close$
$36.40
21.3% upside
Current Fair Value
21.3% upsideUndervalued by 21.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.89 Billion |
|---|---|
| Enterprise Value | $144.49 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-27.86 |
| Beta | 0.41 |
| Outstanding Shares | 94,362,000 |
Return
| Return on Equity | -83.35% |
|---|---|
| Return on Assets | -65.44% |
| Return on Invested Capital | -87.97% |
Valuation & Multiples
| P/E Ratio | -1.25 |
|---|---|
| PEG | -2.01 |
| Price to Sales | - |
| Price to Book Ratio | 1.15 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.07 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.87 |
| Debt to Equity | 0.11 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Modalis Therapeutics Corporation
17 employees
CEO: Haruhiko Morita Modalis Therapeutics Corporation focuses on discovering and developing treatments for severe genetic conditions. The company utilizes its proprietary CRISPR-GNDM technology to create therapies by controlling gene expression through the e...